Idelalisib

Drug Profile

Idelalisib

Alternative Names: CAL-101; GS-1101; Zydelig

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Calistoga Pharmaceuticals
  • Developer Calistoga Pharmaceuticals; Gilead Sciences
  • Class Antineoplastics; Purines; Quinazolinones; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Follicular lymphoma
  • Phase III Non-Hodgkin's lymphoma
  • Phase II Hodgkin's disease; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Phase I Myelofibrosis; Pancreatic cancer
  • Discontinued Allergic rhinitis; Solid tumours

Most Recent Events

  • 10 Jan 2017 Dana-Farber Cancer Institute and Gilead Sciences terminates patient enrolment in a phase II trial for Waldenstrom's macroglobulinaemia due to safety issues from trials in CLL (Second-line therapy or greater) in USA (NCT02439138)
  • 03 Dec 2016 Efficacy and adverse events data from a phase III trial in Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-HEM-2016)
  • 25 Jul 2016 The EMA’s Pharmacovigilance Risk Assessment Committee recommends approval of idelalisib in Chronic lymphocytic leukaemia and Follicular lymphoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top